While the frequency of FGFR2 mutations is highest in endometrial cancer (10–12%), it is below 5% in, e.g., non-small-cell lung cancer (NSCLC), gastric and urothelial cancer. This evidence concerns the gene FGFR2 and non-small cell lung carcinoma.